Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

Established in 1973, the Johns Hopkins cancer centre operates within an academic medical environment linking hospital care, medical education and cancer research. Its Sidney Kimmel name recognises philanthropic support. The centre treats cancers across multiple organ systems rather than functioning as a single-disease hospital.

Its National Cancer Institute comprehensive designation recognises a substantial research programme spanning laboratory, clinical and population-based work. The designation is not a ranking and does not establish that a particular treatment is suitable for every patient. Suitability depends on diagnosis, disease extent, general health and available alternatives.

The centre is a large, multidisciplinary service rather than one ward or building. Care can involve medical oncologists, surgeons, radiation oncologists, haematologists, pathologists and supportive-care professionals. Although this profile focuses on Baltimore, patients should confirm which Johns Hopkins hospital or outpatient site would deliver each component of care.

It is particularly associated with pancreatic and hepatobiliary surgery, blood cancer transplantation and immunotherapy research. These programmes sit alongside broader oncology services. Research activity can inform clinical practice, but experimental approaches remain distinct from established care and require separate discussion of evidence and uncertainty.

Pancreatic cancer and hepatobiliary cancers are important programme areas. Hepatobiliary care encompasses primary liver cancers and bile duct cancers; surgery may also be considered for selected cancers that have spread to the liver. Assessment typically considers imaging, tumour location, blood vessel involvement, liver function and whether treatment before surgery could be appropriate. A surgical consultation does not necessarily lead to an operation.

Blood cancer services address conditions such as leukaemia, lymphoma and myeloma, with bone marrow and blood stem cell transplantation among the relevant treatment pathways. Rare cancers may require specialist pathology review and input from several disease teams. Patients with uncommon diagnoses should ask whether a team routinely manages their precise tumour subtype. Specialist review can refine the diagnosis, but treatment options still depend on the disease's biology, previous therapy and the patient's condition.

Surgery is available within disease-specific programmes, including pancreatic and hepatobiliary care. Decisions about operability require review of disease extent and fitness for a major procedure. International patients should ask about recovery, possible complications and arrangements for urgent assessment after discharge, rather than planning only around the operation itself.

Systemic treatment can include chemotherapy, targeted medicines and immunotherapy. Precision oncology uses molecular information alongside pathology and clinical findings to guide selected decisions. Tumour profiling does not always identify a useful target, and finding a mutation does not automatically mean that an effective or accessible medicine exists.

The centre has an established immunotherapy research heritage, but immunotherapy is not appropriate for all cancers. Its use depends on the diagnosis, biomarkers, previous treatment and potential adverse effects. Radiation therapy may be used alone or with other treatments, with technique and scheduling determined by the tumour's location and treatment aim.

Blood stem cell transplantation requires a separate assessment of disease status, organ function and, where relevant, donor options. It may entail a prolonged local stay and caregiver support. Clinical trials provide another possible pathway, while symptom management, nutrition, rehabilitation and palliative care can support patients alongside cancer-directed treatment.

The supplied profile describes around 700 active oncology clinical trials. This figure is indicative: study numbers change, and 'active' can include trials that are no longer enrolling new participants. The portfolio may include treatment, diagnostic, prevention and supportive-care research. Patients should request a current search for their diagnosis rather than interpret the overall number as evidence that a suitable place is available.

International patients can ask the relevant disease team and international services about trial consideration. Initial screening commonly requires pathology, imaging, previous treatment details and recent laboratory results. Eligibility can depend on molecular findings, organ function, previous medicines and the interval since treatment. A place cannot be assumed before formal screening. Patients should clarify visit frequency, mandatory tests, language requirements and financial responsibility; a study may cover research-specific items without covering routine care, travel or accommodation.

Start with a concise clinical summary and ask Johns Hopkins Medicine International how to submit records securely. Explain whether the request concerns diagnostic confirmation, surgery, systemic treatment, transplantation or a trial. Ask whether any preliminary review can occur before travel and whether original tissue or additional imaging will be needed. Avoid delaying necessary local treatment while awaiting an overseas assessment without discussing this with the treating team.

If care is offered, request a written plan covering the likely sequence of visits, expected time near the hospital, caregiver needs and financial arrangements. Confirm where treatment will take place and how complications will be handled. Arrange a handover to the home oncology team, including prescriptions, monitoring requirements and access to translated treatment summaries where needed.

Contact details below come from the hospital's own published international patient information.

Location: Baltimore, United States

Email: intlservices@jhmi.edu

Phone: +1 410 502 7683

Website: https://www.hopkinsmedicine.org

Languages supported: English, Spanish, Arabic

Remote second opinion: Available

Always confirm current contact details on the hospital's own website before sending medical records, and never send documents to an address you have not verified.